Full-Time
Senior Research Associate
PK/PD Assays
NewLimit
51-200 employees
Develops epigenetic medicines to extend healthspan
Compensation Overview
$90k - $110k/yr
San Bruno, CA, USA
In Person
 Biology & Biotech (2) |
|---|
| , |
- Bachelor’s degree in molecular biology, cell biology, biochemistry, or a related scientific field
- 2+ years of laboratory experience in molecular biology and quantitative assay development (e.g., qPCR, RT-qPCR, ddPCR, ELISA, NGS-based)
- Hands-on experience with primary cell culture, tissue harvesting and complex biological matrices for molecular assays
- Familiarity with bioanalytical assay qualification/validation principles for PK/PD biomarker measurements
- Understanding of data quality, documentation, and experimental practices aligned with preclinical regulatory expectations (e.g., GLP-like practices or bioanalytical method validation guidelines)
- Develop, validate, and execute PK and PD biomarker assays to support preclinical studies and therapeutic discovery programs
- Design and perform molecular biology assays (e.g., qPCR, RT-qPCR, ddPCR, NGS-based assays, ELISA) to quantify nucleic acids, gene and protein expression in biological samples
- Contribute to experimental sample processing and preparation workflows including animal dissections, tissue harvesting, and primary cell culture
- Collaborate with our Epigenetic Editing team to perform large-scale, single cell perturbation experiments
- Perform state-of-the-art single cell profiling experiments to map epigenetic features of aging
- Experience working in environments following GLP or regulated bioanalytical workflows supporting preclinical or IND-enabling studies
- Experience with flow cytometry sorting
- Experience with NGS methods
NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$215M
Headquarters
South San Francisco, California
Founded
2022
Simplify's Take
What believers are saying
- Raised $45M from Eli Lilly at $1.62B valuation in late 2025.
- Achieved 2 prototype liver medicines efficacious in preclinical models by August 2025.
- Conducting IND-enabling studies for liver-rejuvenating mRNA as of February 2026.
What critics are saying
- FDA rejects liver IND due to animal safety signals within 6-12 months.
- Eli Lilly withdraws support after preclinical failures in 12-18 months.
- Retro Biosciences captures first-mover advantage in 12-24 months.
What makes NewLimit unique
- NewLimit reprograms epigenomes using single-cell genomics and machine learning.
- Targets hepatocytes, T cells, and endothelial cells for age-related diseases.
- Develops LNP-mRNA payloads restoring youthful function without cell type change.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at NewLimit who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Unlimited Paid Time Off
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↓ -1%2 year growth
↑ 2%NewLimit, an anti-aging startup founded in 2021 by Coinbase CEO Brian Armstrong, has raised $45 million in new funding, valuing the company at $1.62 billion. The round comes just five months after its Series B, demonstrating rapid growth and strong investor confidence. The company focuses on extending human healthspan by treating age-related diseases. The fresh capital will support groundwork for future clinical studies to advance its technological capabilities. Competition in the longevity sector is intensifying, with OpenAI CEO Sam Altman investing $180 million in rival Retro Biosciences. Despite a 2025 downturn in anti-aging research stocks, NewLimit's successful funding round highlights investor belief in the sector's long-term potential and suggests continued capital flow into this emerging market.
Five months after closing our Series B, NewLimit has raised an additional $45M from Eli Lilly and Company, Duke Management Co, Section 32, and others on a $1.62B cap.
NewLimit, an anti-aging biotech startup co-founded by a cryptocurrency billionaire, has raised $45 million from new investors, including Eli Lilly. This funding positions NewLimit to potentially become biotech's latest unicorn.
NewLimit has successfully raised $129.8 million in equity financing from a total offering amount of $130 million.
NewLimit is developing medicines to extend human healthspan through epigenetic reprogramming